DE60039677D1 - Akt-3 nukleinsäure, polypeptide und deren verwendung - Google Patents

Akt-3 nukleinsäure, polypeptide und deren verwendung

Info

Publication number
DE60039677D1
DE60039677D1 DE60039677T DE60039677T DE60039677D1 DE 60039677 D1 DE60039677 D1 DE 60039677D1 DE 60039677 T DE60039677 T DE 60039677T DE 60039677 T DE60039677 T DE 60039677T DE 60039677 D1 DE60039677 D1 DE 60039677D1
Authority
DE
Germany
Prior art keywords
polypeptides
akt
nucleic acid
akt3
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60039677T
Other languages
German (de)
English (en)
Inventor
Kun Guo
Marco F Pagnoni
Kenneth L Clark
Yuri D Ivashchenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60039677D1 publication Critical patent/DE60039677D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60039677T 1999-03-19 2000-03-14 Akt-3 nukleinsäure, polypeptide und deren verwendung Expired - Lifetime DE60039677D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12510899P 1999-03-19 1999-03-19
PCT/US2000/006574 WO2000056866A2 (en) 1999-03-19 2000-03-14 Akt-3 nucleic acids, polypeptides, and uses thereof

Publications (1)

Publication Number Publication Date
DE60039677D1 true DE60039677D1 (de) 2008-09-11

Family

ID=22418217

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60039677T Expired - Lifetime DE60039677D1 (de) 1999-03-19 2000-03-14 Akt-3 nukleinsäure, polypeptide und deren verwendung

Country Status (18)

Country Link
EP (1) EP1144600B1 (https=)
JP (1) JP4237945B2 (https=)
KR (1) KR100700908B1 (https=)
AT (1) ATE402995T1 (https=)
AU (1) AU782448B2 (https=)
BR (1) BR0009170A (https=)
CA (1) CA2343074C (https=)
CY (1) CY1108459T1 (https=)
DE (1) DE60039677D1 (https=)
DK (1) DK1144600T3 (https=)
ES (1) ES2310515T3 (https=)
HK (1) HK1041288B (https=)
IL (4) IL141984A0 (https=)
NO (1) NO20014537L (https=)
PT (1) PT1144600E (https=)
SI (1) SI1144600T1 (https=)
WO (1) WO2000056866A2 (https=)
ZA (1) ZA200108414B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
MXPA01010459A (es) 1999-04-16 2003-08-20 Univ Yale Mutaciones de sintasa de oxido nitrico endotelial, utiles para terapia con genes y su depuracion terapeutica.
CZ20014444A3 (cs) * 1999-06-11 2002-05-15 Aventis Pharmaceuticals Products Inc. Protein Akt pro pouľití k indukci exprese VEGF
JPWO2003063905A1 (ja) * 2002-01-31 2005-05-26 株式会社東京大学Ｔｌｏ 免疫疾患の予防又は治療剤
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
WO2005009470A1 (ja) * 2003-07-28 2005-02-03 Osaka Industrial Promotion Organization Ａｓｋ１阻害剤を有効成分とする心不全治療薬およびそのスクリーニング方法
WO2009148896A2 (en) * 2008-05-29 2009-12-10 Nuclea Biotechnologies, LLC Anti-phospho-akt antibodies
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
NZ604831A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc Apoptosis signal-regulating kinase inhibitors
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
MX2017003933A (es) 2014-09-24 2017-06-30 Gilead Sciences Inc Metodos de tratamiento de la enfermedad hepatica.
CN112225699B (zh) 2014-12-23 2023-11-14 吉利德科学公司 制备ask1抑制剂的方法
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
CN113795279B (zh) * 2019-03-04 2024-12-31 宾夕法尼亚州大学信托人 靶向akt通路的神经保护性基因疗法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08109197A (ja) * 1994-10-07 1996-04-30 Sumitomo Electric Ind Ltd 白血病腫瘍拒絶抗原ペプチド
PT862622E (pt) * 1995-11-16 2005-01-31 Novartis Ag Metodo de rastreio para compostos que interagem com proteina cinase rac
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
GB9828375D0 (en) * 1998-12-22 1999-02-17 Janssen Pharmaceutica Nv Human akt-3
US6043090A (en) * 1999-03-23 2000-03-28 Isis Pharmaceuticals Inc. Antisense inhibition of human Akt-2 expression
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
CZ20014444A3 (cs) * 1999-06-11 2002-05-15 Aventis Pharmaceuticals Products Inc. Protein Akt pro pouľití k indukci exprese VEGF

Also Published As

Publication number Publication date
NO20014537D0 (no) 2001-09-18
ATE402995T1 (de) 2008-08-15
WO2000056866A3 (en) 2001-02-15
AU782448B2 (en) 2005-07-28
DK1144600T3 (da) 2008-11-24
KR20020011972A (ko) 2002-02-09
KR100700908B1 (ko) 2007-03-29
JP2002539781A (ja) 2002-11-26
WO2000056866A9 (en) 2002-08-29
EP1144600A2 (en) 2001-10-17
PT1144600E (pt) 2008-10-10
IL190270A (en) 2012-12-31
HK1041288A1 (en) 2002-07-05
NO20014537L (no) 2001-10-31
BR0009170A (pt) 2002-04-30
SI1144600T1 (sl) 2008-12-31
CA2343074C (en) 2010-09-21
JP4237945B2 (ja) 2009-03-11
IL145514A (en) 2010-05-17
HK1041288B (en) 2008-11-07
AU3880200A (en) 2000-10-09
IL145514A0 (en) 2002-06-30
CY1108459T1 (el) 2013-09-04
CA2343074A1 (en) 2000-09-28
ZA200108414B (en) 2003-03-26
ES2310515T3 (es) 2009-01-16
EP1144600B1 (en) 2008-07-30
WO2000056866A2 (en) 2000-09-28
IL141984A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
DK0559884T4 (da) Rekombinante virusvektorer til ekspression i muskelceller
DK1317537T3 (da) Sammensætninger og fremgangsmåder med G-CSF analoger
DE3684892D1 (de) Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens.
DE602005021509D1 (de) Modifizierte vitamin-k-abhängige polypeptide
DE69837996D1 (de) Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
DK1032672T3 (da) DNA19355-polypeptid, en tumornekrosefaktor-homolog
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
EP0232523A3 (en) Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
TR200102985T2 (tr) Gen tedavisi teknikleri.
BR0212070A (pt) ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
BR9812138A (pt) Métodos e composições para terapias empregando genes codificando proteìnas segregadas tal como interferon-beta
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
DE69831231D1 (de) Modulatoren von intrazellulären entzündungs-, zelltod- und zellüberlebenswegen, die card- und kinase-domänen enthalten
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
HUP0001057A2 (hu) A szarvasmarhafélék laktációjával összefüggő fehérje (CD14), az azt kódoló gén és a fehérje B-sejt-aktiválásban való alkalmazása
DK0676413T3 (da) Inteferon-alfa/beta-bindingsprotein, dets fremstilling og anvendelse
BRPI0415296A (pt) cdna modificado para os nìveis de expressão elevados do fator viii e seus derivados
ATE466588T1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
EP1427825B8 (en) Cdna encoding the human alpha2 delta4 calcium channel subunit
EE04819B1 (et) Rekombinantne DNA molekul ja ekspressioonivektorit sisaldav peremeesrakk
WO2002034882A3 (en) Genes regulating programmed cell death

Legal Events

Date Code Title Description
8364 No opposition during term of opposition